Oscar Health, Inc. OSCR
35.19 USD +2.78 (+8.58%)
At closeNov 4, 2026, 6:34 PM EST
35.12 -0.07 -0.19%
After hours · Nov 4, 6:34 PM ET
33.24 Day range 36.16
10.69 52-week range 36.16
- YTD
- +144.89%
- 1 year
- +105.07%
Analyst view
Consensus: hold
Hold
Price target (mean) 36.40 +3.4% upside
Now 35.19
- Target (low)
- 27.00
- Target (mean)
- 36.40
- Target (high)
- 49.00
Ratings (0m) 11 3 buy · 7 hold · 1 sell
- Strong buy3
- Buy0
- Hold7
- Sell0
- Strong sell1
Recommendation trend
- This month 11
- 1 month ago 11
- 2 months ago 11
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.17339 | -0.40 – 0.07 | -0.53 | +67.3% | 4.72B | +58.0% | 7 |
| Next quarter | -1.08 | -1.30 – -0.95 | -1.24 | +12.8% | 4.48B | +59.5% | 7 |
| Current year | 1.94 | 1.80 – 2.12 | -1.69 | +215.0% | 18.73B | +60.1% | 8 |
| Next year | 2.22 | 2.00 – 2.35 | 1.94 | +14.3% | 20.78B | +10.9% | 8 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | UBS | Maintained | Neutral | Neutral |
| Sep 18, 2026 | Raymond James | Maintained | Outperform | Outperform |
| Sep 17, 2026 | B of A Securities | Maintained | Underperform | Underperform |
| Sep 17, 2026 | Stephens & Co. | Reiterated | Equal-Weight | Equal-Weight |
| Sep 17, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 17, 2026 | Baird | Maintained | Neutral | Neutral |
| Aug 13, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Aug 7, 2026 | UBS | Maintained | Neutral | Neutral |
| Aug 7, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jun 10, 2026 | Barclays | Upgrade | Equal-Weight | Overweight |
| May 26, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| May 7, 2026 | UBS | Maintained | Neutral | Neutral |
| May 7, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| May 7, 2026 | Baird | Maintained | Neutral | Neutral |
| May 6, 2026 | Wolfe Research | Initiated | — | Peer Perform |
| Apr 20, 2026 | Jefferies | Upgrade | Underperform | Hold |
| Jan 9, 2026 | UBS | Upgrade | Sell | Neutral |
| Jan 5, 2026 | Barclays | Upgrade | Underweight | Equal-Weight |
| Dec 11, 2025 | Stephens & Co. | Initiated | — | Equal-Weight |
| Nov 26, 2025 | Piper Sandler | Upgrade | Neutral | Overweight |
| Nov 13, 2025 | Wells Fargo | Maintained | Underweight | Underweight |
| Nov 10, 2025 | Barclays | Maintained | Underweight | Underweight |
| Nov 7, 2025 | UBS | Maintained | Sell | Sell |
| Oct 14, 2025 | Goldman Sachs | Initiated | — | Neutral |
| Oct 7, 2025 | Wells Fargo | Maintained | Underweight | Underweight |
| Aug 14, 2025 | Piper Sandler | Maintained | Neutral | Neutral |
| Jul 25, 2025 | Baird | Downgrade | Outperform | Neutral |
| Jul 23, 2025 | Barclays | Maintained | Underweight | Underweight |
| Jul 15, 2025 | UBS | Downgrade | Neutral | Sell |
| Jul 11, 2025 | Wells Fargo | Downgrade | Equal-Weight | Underweight |
